Breaking the malignant triangle in glioblastoma - ErbB1/nucleoin/Ras

Sari Schokoroy Trangle, Yona Goldshmit, Yoel Kloog, Ronit Pinkas-Kramarski


Glioblastoma is one of the most malignant tumors in humans, with poor diagnosis and a low survival rate. These tumors overexpress the ErbB1 receptor and have high levels of cell surface nucleolin, which serves as an indicator for disease grade. We have previously identified a crosstalk between three oncogenes: ErbB1, Ras and nucleolin. This lead us to suggest a combined treatment using FTS, to target Ras protein, and GroA, to target cell surface nucleolin, in order to break this malignant synergy. Here we review our recent findings and suggest a model explaining drugs activities:  inhibition of Ras using FTS mainly reduces cell viability and motility and inhibition of nucleolin using GroA reduces the cell proliferation. The combined treatment has a more pronounced effect on glioblastoma growth.

Full Text:




  • There are currently no refbacks.

Copyright (c) 2014 Ronit Pinkas-Kramarski, Sari Schokoroy Trangle, Yona Goldshmit, Yoel Kloog

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.